盐酸美金刚治疗轻中度阿尔茨海默病的临床研究

Efficacy and safety of memantine in the treatment of mild to moderate Alzheimer disease

目的 探讨盐酸美金刚治疗轻中度阿尔茨海默病的有效性和安全性.方法 使用简易智能状态量表（MMSE）筛选出轻、中度AD患者（评分在10～23分之间）,并对其进行12周盐酸美金刚治疗.分别于治疗前、治疗后4、12周对AD患者进行MMSE、Alzheimer病评估量表（ADAS-cog）、日常生活自理量表（ADL）评定,同时评定药物的不良反应.结果 50例轻中度AD患者盐酸美金刚治疗4周时,AD患者的MMSE、ADAS-cog和ADL指标已有所改善（P＜0.05）,治疗12周末较治疗前有显著改善（P＜0.01）.50例AD患者盐酸美金刚治疗后12w共有4例（8%）患者出现不良反应.1例出现头疼和头晕,1例出现贫血,1例出现轻度幻觉,1例表现为疲劳.不良反应经对症治疗后均好转,无死亡病例.结论 盐酸美金例不但能明显改善轻中度AD患者的认知功能和日常生活自理能力,而且具有较高的临床安全性.

Objective To evaluate the efficacy and safety of memantine hydrochloride in the treatment of mild to moderate Alzheimer＇s disease （AD）. Methods The patients with mild to moderate AD were screened using mini-mental state examination （MMSE） and were assessed by ADAS-cog and activity of daily living scale （ADL） before and 4 and 12 weeks after memantine therapy. The reverse reactions of memantine were recorded. Results Fifty patients with mild to moderate AD were enrolled this study. There was improve-ment in cognition and behavior by the end of 4 weeks after therapy （P〈0.05）. By the end of 12 weeks, there was significant improvement in cognition and behavior on the assessment of MMSE, ADAS-cog, and ADL. Only mild side effects occurred in 4 patients. Conclusions Mementine is a safe and effective drug for mild to moderate AD with improvement in cognitive function and activities of daily living.